Treatment Outcomes of HER-2 Positive Metastatic Breast Cancer Patients Treated with Pertuzumab in the First Line Setting- Real Life Experience
INTRODUCTION: Pertuzumab is a new recombinant humanized monoclonal antibody, has been developed to inhibit the formation of HER2: HER3 heterodimerization. The clinical benefit of pertuzumab therapy in HER2 positive metastatic Breast Cancer (mBC) patients in the first-line setting has been shown in p...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Van Yuzuncu Yil University, School of Medicine
2019-04-01
|
| Sarja: | Van Tıp Dergisi |
| Aiheet: | |
| Linkit: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-58966 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|